• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

    62.05 -1.46 (-2.30%)
    Streaming Delayed Price Updated: 3:48 PM EST, Feb 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 424,822
    Open 63.68
    Bid (Size) 62.02 (100)
    Ask (Size) 62.16 (1,000)
    Prev. Close 63.51
    Today's Range 61.67 - 65.08
    52wk Range 38.51 - 85.25
    Shares Outstanding 34,200,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Combines High-Growth Momentum with a Favorable Technical Setup ↗
    Via Chartmill
    News headline image
    TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows High-Growth Momentum and Technical Setup for Breakout ↗
    Tarsus Pharmaceuticals (TARS) combines explosive revenue growth with a strong technical setup, presenting a potential breakout opportunity for momentum investors. 
    Via Chartmill

    Performance

    YTD
    -23.2%
    -23.2%
    1 Month
    -22.2%
    -22.2%
    3 Month
    -9.0%
    -9.0%
    6 Month
    +49.0%
    +49.0%
    1 Year
    +13.9%
    +13.9%

    More News

    Read More
    News headline image
    Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
    Via The Motley Fool
    News headline image
    Tarsus to Participate in Upcoming Investor Conference
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 6, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For May 1, 2025 ↗
    Via Benzinga
    News headline image
    TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Technical Health and Growth Momentum ↗
    Via Chartmill
    News headline image
    TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Growth Momentum and Technical Setup ↗
    Via Chartmill
    News headline image
    Tarsus to Participate in Upcoming Investor Conference
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗
    Via The Motley Fool
    News headline image
    Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗
    Via The Motley Fool
    News headline image
    Tarsus to Participate in Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    3 Biotech Catalysts Present Major Opportunity ↗
    Via MarketBeat
    News headline image
    Top 2 Health Care Stocks That May Fall Off A Cliff In August ↗
    Via Benzinga
    News headline image
    Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus to Participate in Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
    Via Benzinga
    News headline image
    Tarsus to Participate in Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know ↗
    Via Benzinga
    News headline image
    Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal ↗
    Via Benzinga
    News headline image
    Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire

    Frequently Asked Questions

    Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?
    Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market
    What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?
    The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 62.05
    When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 02/05/26 03:48 PM ET
    What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 2.12B
    How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?
    Tarsus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.